The Global Biological Sample Collection Kits Market was valued at USD 9.2 billion in 2024 and is estimated to grow at a CAGR of 7.7% to reach USD 19.7 billion by 2034.
The market continues to grow as demand rises for diagnostic testing, biobanking, and personalized medicine initiatives that rely heavily on accurate biomarker analysis. These kits support laboratories, healthcare facilities, diagnostics companies, and biopharmaceutical organizations by preserving sample quality and ensuring dependable results. A wide range of products, such as blood and urine collection kits, viral transport media, saliva-based systems, and self-sampling tools, enable safe, consistent, contamination-free handling for both clinical and research purposes. The shift toward molecular diagnostics, including next-generation sequencing and PCR-based testing, is expanding the need for specialized kits optimized for advanced analytical platforms. Increasing use of telemedicine is also accelerating the adoption of at-home collection solutions that offer patient convenience and reduce the burden on clinical settings. Additionally, regulatory attention on sample security and traceability is encouraging innovation in barcoded packaging, tamper-resistant designs, and temperature-stable formats. Growing automation in laboratories and the push for kits tailored to specific specimen types are further supporting long-term market momentum.
The swabs segment is expected to grow at a CAGR of 7.2% through 2034. Growth is influenced by increasing demand for non-invasive sampling across infectious disease diagnostics, microbiome research, and rapid testing workflows. Their reliability and widespread availability make swabs essential in hospitals, laboratory settings, and point-of-care environments.
The diagnostics segment held a 78.9% share in 2024 and is anticipated to achieve USD 15.8 billion by 2034. Rising rates of chronic and infectious illnesses worldwide are driving consistent use of diagnostic testing to support early detection and treatment planning. Collection kits form a critical part of these workflows by maintaining sample integrity and helping reduce medical costs through timely health assessments.
North America Biological Sample Collection Kits Market accounted for a 32.4% share in 2024. Strong healthcare infrastructure, broad access to advanced diagnostic technologies, and robust research ecosystems continue to support high utilization of biological sampling kits. Increasing case numbers for metabolic, cardiac, oncological, and infectious conditions further reinforce the need for reliable diagnostic tools across the region.
Leading companies active in the Global Biological Sample Collection Kits Market include Abbott, Altona Diagnostics, Becton, Dickinson and Company (BD), CTK Biotech, Hardy Diagnostics, HiMedia Laboratories, Labcorp, Lucence Health, Miraclean Technology, Puritan Medical, QIAGEN, Roche, Seegene, Thermo Fisher Scientific, and VIRCELL MEDICAL. Companies competing in the Biological Sample Collection Kits Market use a variety of strategies to strengthen their presence. Many are expanding product portfolios with specialized kits that support molecular testing, personalized medicine, and at-home diagnostics. Investments in automation-ready systems, tamper-proof designs, and advanced tracking features help improve accuracy and traceability. Firms are enhancing global distribution networks and forming partnerships with laboratories, biotech companies, and healthcare providers to widen market access. Significant focus is placed on compliance with evolving regulatory standards to ensure product reliability across regions.
This product will be delivered within 2-4 business days.
The market continues to grow as demand rises for diagnostic testing, biobanking, and personalized medicine initiatives that rely heavily on accurate biomarker analysis. These kits support laboratories, healthcare facilities, diagnostics companies, and biopharmaceutical organizations by preserving sample quality and ensuring dependable results. A wide range of products, such as blood and urine collection kits, viral transport media, saliva-based systems, and self-sampling tools, enable safe, consistent, contamination-free handling for both clinical and research purposes. The shift toward molecular diagnostics, including next-generation sequencing and PCR-based testing, is expanding the need for specialized kits optimized for advanced analytical platforms. Increasing use of telemedicine is also accelerating the adoption of at-home collection solutions that offer patient convenience and reduce the burden on clinical settings. Additionally, regulatory attention on sample security and traceability is encouraging innovation in barcoded packaging, tamper-resistant designs, and temperature-stable formats. Growing automation in laboratories and the push for kits tailored to specific specimen types are further supporting long-term market momentum.
The swabs segment is expected to grow at a CAGR of 7.2% through 2034. Growth is influenced by increasing demand for non-invasive sampling across infectious disease diagnostics, microbiome research, and rapid testing workflows. Their reliability and widespread availability make swabs essential in hospitals, laboratory settings, and point-of-care environments.
The diagnostics segment held a 78.9% share in 2024 and is anticipated to achieve USD 15.8 billion by 2034. Rising rates of chronic and infectious illnesses worldwide are driving consistent use of diagnostic testing to support early detection and treatment planning. Collection kits form a critical part of these workflows by maintaining sample integrity and helping reduce medical costs through timely health assessments.
North America Biological Sample Collection Kits Market accounted for a 32.4% share in 2024. Strong healthcare infrastructure, broad access to advanced diagnostic technologies, and robust research ecosystems continue to support high utilization of biological sampling kits. Increasing case numbers for metabolic, cardiac, oncological, and infectious conditions further reinforce the need for reliable diagnostic tools across the region.
Leading companies active in the Global Biological Sample Collection Kits Market include Abbott, Altona Diagnostics, Becton, Dickinson and Company (BD), CTK Biotech, Hardy Diagnostics, HiMedia Laboratories, Labcorp, Lucence Health, Miraclean Technology, Puritan Medical, QIAGEN, Roche, Seegene, Thermo Fisher Scientific, and VIRCELL MEDICAL. Companies competing in the Biological Sample Collection Kits Market use a variety of strategies to strengthen their presence. Many are expanding product portfolios with specialized kits that support molecular testing, personalized medicine, and at-home diagnostics. Investments in automation-ready systems, tamper-proof designs, and advanced tracking features help improve accuracy and traceability. Firms are enhancing global distribution networks and forming partnerships with laboratories, biotech companies, and healthcare providers to widen market access. Significant focus is placed on compliance with evolving regulatory standards to ensure product reliability across regions.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn, Units)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies profiled in this Biological Sample Collection Kits market report include:- Abbott
- Altona Diagnostics
- Becton, Dickinson and Company (BD)
- CTK Biotech
- Hardy Diagnostics
- HiMedia Laboratories
- Labcorp
- Lucence Health
- Miraclean Technology
- Puritan Medical
- QIAGEN
- Roche
- Seegene
- Thermo Fisher Scientific
- VIRCELL MEDICAL
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | December 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 9.2 Billion |
| Forecasted Market Value ( USD | $ 19.7 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
